Inflammation Cytokine Expression and Association With Clinical Outcomes in Critically Ill Patients After Major Surgery: A Retrospective Cohort Study

Yamin Yan

Zhongshan Hospital Fudan University

Xiaorong Wang

Zhongshan Hospital Fudan University

Yan Hu

Zhongshan Hospital Fudan University

Zhenghong Yu

Shanghai Stomatological Disease Center

Yingjia Tang

Zhongshan Hospital Fudan University

Jingjing Li

Zhongshan Hospital Fudan University

Jinghua Mei

Zhongshan Hospital Fudan University

Wenyan Pan (✉ panwenyan1987@126.com)

Zhongshan Hospital Fudan University <https://orcid.org/0000-0003-0624-0390>

Yuxia Zhang

Zhongshan Hospital Fudan University

Research

Keywords: Cytokine expression, major surgery, critical ill patients, mortality, SICU readmission

Posted Date: June 4th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-32628/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background The associations of serum cytokine levels and critically ill patient outcomes after major surgery remain unclear. The use of cytokine markers to predict outcomes in critically ill patients is controversial.

Objective To determine the levels of IL-1 β , IL-2, IL-6, IL-8, IL-10, TNF- α and procalcitonin in critical surgical ICU(SICU) patients and evaluate their associations with patient outcome and clinical significance.

Methods This was a retrospective cohort study of consecutive patients admitted to the SICU in Zhongshan Hospital, Fudan University. The program ran from January 1, 2018, to June 30, 2019. The levels of IL-1 β , IL-2, IL-6, IL-8, IL-10, TNF- α and procalcitonin were detected, and their relationship with patient outcomes was investigated. The primary outcome was in-hospital mortality, compared by a multivariable logistic regression analysis among the survivors and nonsurvivors.

Results Overall, 5,257 patients were included in this study for their first SICU admission; 5,099 patients survived, 158 patients died, and the mortality rate was 3.0%(158/5,257). Univariate and multivariate analyses showed that nonsurvivors had increased levels of IL-1(OR=1.855, P=0.000) and IL-2(OR=1.51, P=0.000) compared with survivors. In addition, 196 patients(3.7%) were readmitted to the SICU, and data from 187 patients were collected. Of these, 161 patients survived, and 26 patients died; the mortality rate was 13.9%(26/187), which was much higher than that of the first round of patients. The level of IL-2 significantly influenced SICU readmission(OR=3.921, P=0.000). For the third round of SICU admission, 10 patients were included, 7 patients survived, and 3 patients died; the mortality rate was 30.0%(3/10). Furthermore, older age, longer time of SICU stay, and higher rate of mechanical ventilation and CRRT were associated with patient death.

Conclusions High levels of cytokines may be risk factors for mortality and SICU readmission in critically ill patients who receive major surgery. Further work is still needed to determine which unmeasured characteristics and therapies may contribute to the increased risk observed.

Background

Despite advances in the management of critically ill patients, mortality among the ICU population remains high. Outcome prediction could provide useful information regarding therapeutic decision making and guide resource allocation[1]. However, the prediction of ICU mortality is still challenging.

There is mounting evidence indicating that cytokines are implicated in the pathogenesis of critical illness[2]. The occurrence and development of illness are closely associated with the human immune system. Cytokines play an important role in regulating the immunologic response, which mediates the severity of disease and associated complications. For example, IL-2, an important component of cellular immunity that promotes the differentiation of activated T cells, directly affects the function of immune cells and the local immune status[3]. In critically ill states, high levels of inflammatory cytokines are

positively related to the severity of underlying disease, and their persistence in the circulation and intense activation of inflammatory mediators play important roles in the development of multiple organ failure (MOF)[4, 5]. The serum level of IL-6 is associated with clinical outcome or organ dysfunction severity in critically ill patients[6, 7] and may be useful for predicting the development of acute kidney injury. In sepsis, the balance between tumor necrosis factor-alpha (TNF- α) and interleukin-10 (IL-10) determines clinical outcome[8].

Cytokine responses in critically ill patients who have just undergone surgery have been less investigated. In particular, the associations between cytokine expression and outcomes in such patients have not been well defined. A variety of pro- and anti-inflammatory mediators seem to be involved in the pathogenesis of systemic inflammatory response syndrome (SIRS)[9] after operation; however, the pattern of their evolution during the course of SIRS remains largely unexplored. One study reported that early after the end of the operation, IL-6, IL-8 and IL-10 were elevated compared to their baseline levels. These increases were followed by increases in TNF- α , which was increased after one day. Moreover, it was shown that the balance between TNF- α and IL-10 may be related to the occurrence of postoperative complications[10].

The purpose of this study was to identify the expression levels of IL-1 β , IL-2, IL-6, IL-8, IL-10, TNF- α and procalcitonin in critical surgical ICU (SICU) patients and to investigate whether the expression level is associated with key clinical outcomes such as ICU readmission and mortality risk in SICU patients. Furthermore, in readmitted patients, we evaluated the correlation between cytokine levels and patient mortality and the rate of a third readmission to the SICU.

Materials And Methods

Setting and patients

Before the analysis, all the patients' information was anonymized and deidentified. All participants provided written informed consent.

This study was conducted in the SICU in a teaching hospital that has 28 beds and included all mechanically ventilated, critically ill patients who received surgery. Adult (≥ 18 years of age) critically ill patients who recently received surgery were enrolled. Patients were excluded if baseline data were missing or data on serum cytokine expression levels on SICU admission were lacking. In total, 5,257 patients were enrolled.

Data Collection

We extracted the following data of critically ill patients who received surgery: demographics, diagnosis, surgical status and urgency (emergency surgery or elective surgery), cytokine level (IL-1 β , IL-2, IL-6, IL-8, IL-10, TNF- α and procalcitonin), type of organ support (i.e., mechanical ventilation or continuous renal replacement therapy (CRRT)), etc. The data of age, sex, admitting diagnosis, and severity of illness were

recorded upon entry into the SICU. Data were collected daily by trained data collectors from the time of SICU admission to death or SICU discharge. Data included in this study were collected between January 1, 2018, and June 31, 2019.

These analyses were carried out retrospectively, and informed consent was required. The procedure mentioned in this study was in accordance with the standards of the Ethics Committee for Human Experimentation of Zhongshan Hospital, Fudan University.

Cytokine Measurements

Blood samples were collected within 24 h of SICU admission to check the expression levels of IL-1 β , IL-2, IL-6, IL-8, IL-10, TNF- α and procalcitonin. Concentrations of these parameters were measured in duplicate after staining with monoclonal antibodies and passage through IMMULITE 1000 Immunoassay System (Siemens, Berlin). Normal levels of detection were lower than 5 pg/ml for IL-1 β , 223–710 U/ml for IL-2, lower than 3.4 pg/ml for IL-6, lower than 62 pg/ml for IL-8, lower than 9.1 pg/ml for IL-10, lower than 8.1 pg/ml for TNF- α and lower than 0.5 ng/ml for procalcitonin.

Outcomes

The primary outcome was hospital mortality. Secondary outcomes included several SICU-specific outcomes: SICU readmission, SICU length of stay, receipt of tracheostomy, total days of organ support, receipt and duration of mechanical ventilation at any time during SICU admission, and receipt and duration of renal replacement therapy. Mechanical ventilation was defined as positive pressure ventilation via an endotracheal tube or tracheostomy. Renal replacement therapy included all forms of continuous renal replacement therapy and intermittent hemodialysis.

Statistical analysis

All statistical analyses were conducted using the statistical package SPSS for Windows (Version 22.0, SPSS, Chicago, IL). Data are presented as medians and interquartile ranges (IQRs) for data that did not follow a normal distribution and as the means $\pm$ standard deviations (SDs) for parameters that followed a normal distribution. Between-group comparisons were performed with Student's t-test or the Mann-Whitney-Wilcoxon test. Outcome frequency was examined using descriptive statistics. The chi-square test or Fisher's exact test was used for univariate analysis of the collected variables. Multilevel mixed-effects logistic regression analysis was performed to examine the association between cytokine expression level and hospital mortality. The odds ratios (ORs) and 95% confidence intervals (CI) are reported. Those variables that were significantly related to outcome were also included in a multivariate logistic regression analysis to examine their independent effect on outcome. Kaplan-Meier survival curves were plotted and compared using the log-rank test for overall survival analysis. Time to events (death or

readmission) was defined as the time from SICU admission to the event being analyzed. A P value < 0.05 was considered to show statistical significance.

Results

Demographics and clinical characteristics A total of 5,257 patients were included in this study. The mean age of the nonsurvivors was 69.7 ± 17.1 years, which was older than that of survivors. Overall, 5,099 patients survived, and 158 patients died, yielding a mortality rate of 3.0%. Death occurred 1–228 days following SICU admission. In the nonsurvivor group, the length of SICU stay and length of mechanical ventilation were much longer than those in the survivor group; the rates of SICU readmission, mechanical ventilation, CRRT, tracheotomy and emergency surgery were much higher in the nonsurvivor group than the survivor group. According to the department, the highest mortality rate occurred in the general surgery department (6.2%), and the lowest occurred in the thoracic surgery department (0.5%). The demographics and clinical characteristics of survivors and nonsurvivors are shown in Table 1.

Table 1
Baseline patient characteristics (n = 5,257)

Variables	Outcome (n = 5,257)		t/z/χ ²	P value
	Nonsurvivors (n = 158)	Survivors (n = 5,099)		
Age (year)	69.7 ± 17.1	62.1 ± 16.2	5.748	0.000
Sex, No. (%)			0.611	0.434
Male	99 (3.2%)	3,037 (96.8%)		
Female	59 (2.8%)	2,062 (97.2%)		
Length of SICU stay (h)	338.5 ± 649.6	63.7 ± 144.7	15.575	0.000
Length of SICU stay			326.208	0.000
≥7 days	65 (19.2%)	273 (80.8%)		
≤7 days	93 (1.9%)	4,826 (98.1%)		
SICU readmission			88.864	0.000
Yes	28 (14.3%)	168 (85.7%)		
No	130 (2.6%)	4,931 (97.4%)		
Mechanical ventilation			394.924	0.000
Yes	141 (11.5%)	1,087 (88.5%)		
No	17 (0.4%)	4,012 (99.6%)		
Length of mechanical ventilation (h)	396.0 ± 774.7	109.7 ± 311.9	8.262	0.000
Tracheotomy				
Yes	49 (19.4%)	203 (80.6%)	245.402	0.000
No	109 (2.2%)	4,896 (97.8%)		
CRRT			315.779	0.000
Yes	45 (25.4%)	132 (74.6%)		
No	113 (2.2%)	4,967 (97.8%)		
Length of CRRT (h)	87.6 ± 83.0	70.7 ± 94.8	1.071	0.286
Emergency surgery			145.588	0.000

SICU surgical intensive care unit, TNF-α tumor necrosis factor-α, IL interleukin, CRRT continuous renal replacement therapy

Variables	Outcome (n = 5,257)		t/z/χ ²	P value
	Nonsurvivors (n = 158)	Survivors (n = 5,099)		
Yes	149 (9.6%)	1,406 (90.4%)		
No	8 (0.2%)	3,679 (99.8%)		
Not known	1 (6.7%)	14 (93.3%)		
Department			71.338	0.000
General surgery	76 (6.2%)	1,152 (93.8%)		
Thoracic surgery	6 (0.5%)	1,267 (99.5%)		
Orthopedics	11 (2.6%)	406 (97.4%)		
Neurosurgery	26 (3.3%)	772 (96.7%)		
Endovascular surgery	23 (4.1%)	535 (95.9%)		
Urologic surgery	4 (1.3%)	313 (98.7%)		
Others	12 (1.8%)	654 (98.2%)		
SICU surgical intensive care unit, TNF-α tumor necrosis factor-α, IL interleukin, CRRT continuous renal replacement therapy				

Cytokine levels were increased in nonsurvivors To determine whether cytokine levels were associated with hospital mortality, we assessed the difference between survivors and nonsurvivors. Nonsurvivors had increased levels of IL-1β, IL-2, IL-6, IL-8, IL-10, TNF-α and procalcitonin compared with survivors (Table 2). Univariate and multivariate analyses showed that there was a significant correlation between the levels of IL-1β and IL-2 and outcomes, but no correlation was noted between IL-6, IL-8, IL-10, TNF-α and procalcitonin expression and outcomes in the patients (Table 3).

Table 2
Cytokine levels in survivors and nonsurvivors (n = 5,257)

Cytokines	Outcome (n = 5,257)		z	P value
	Nonsurvivors (n = 158)	Survivors (n = 5,099)		
IL-1 β (pg/ml)			-10.415	0.000
Normal (≤ 5)	128 (2.5%)	4,922 (97.5%)		
5 ~ 10	12 (9.0%)	121 (91.0%)		
≥ 10	18 (24.3%)	56 (75.7%)		
IL-2 (U/ml)			-14.487	0.000
Normal (223–710)	31 (1.0%)	3,181 (99.0%)		
710-1,000	22 (2.3%)	922 (97.7%)		
1,000–2,000	51 (5.8%)	786 (94.2%)		
2,000–3,000	27 (16.3%)	139 (83.7%)		
$\geq 3,000$	27 (27.6%)	71 (72.4%)		
IL-6 (pg/ml)			-8.93	0.000
Normal (≤ 3.4)	3 (0.8%)	387 (99.2%)		
3.4–50	46 (1.6%)	2,756 (98.4%)		
50–100	29 (3.7%)	762 (96.3%)		
100–200	22 (3.7%)	578 (96.3%)		
≥ 200	58 (8.6%)	616 (91.4%)		
IL-8 (pg/ml)			-10.964	0.000
Normal (< 62)	87 (1.9%)	4,378 (98.1%)		
62–100	22 (6.9%)	295 (93.1%)		
100–150	13 (7.6%)	159 (92.4%)		
150–200	5 (5.2%)	92 (94.8%)		
≥ 200	31 (15.0%)	175 (85.0%)		
IL-10 (pg/ml)			-9.474	0.000
Normal (< 9.1)	79 (1.9%)	3,994 (98.1%)		
TNF- α tumor necrosis factor-alpha, IL interleukin				

9.1–20	25 (3.6%)	675 (96.4%)		
20–50	19 (6.4%)	278 (93.6%)		
50–100	11 (12.5%)	77 (87.5%)		
≥ 100	24 (24.2%)	75 (75.8%)		
TNF-α (pg/ml)			-10.544	0.000
Normal (< 8.1)	21 (0.9%)	2,330 (99.1%)		
8.1–15	47 (2.8%)	1,642 (97.2%)		
15–30	40 (4.8%)	797 (95.2%)		
30–50	26 (10.9%)	212 (89.1%)		
≥ 50	24 (16.9%)	118 (83.1%)		
Procalcitonin (ng/ml)			-10.938	0.000
Normal (< 0.5)	72 (1.9%)	3,706 (98.1%)		
0.5-2	27 (3.4%)	766 (96.6%)		
2–5	17 (5.7%)	281 (94.3%)		
5–10	13 (6.5%)	188 (93.5%)		
≥ 10	29 (15.5%)	158 (84.5%)		
TNF-α tumor necrosis factor-alpha, IL interleukin				

Table 3
Analysis of cytokine levels in relation to outcomes of patients

Variables	β	SE	P value	OR	95% CI
Univariate analysis					
Sex	-0.183	0.214	0.392	0.833	(0.547, 1.267)
Length of SICU stay	-0.949	0.219	0.000	0.387	(0.252, 0.595)
SICU readmission	0.933	0.286	0.001	2.543	(1.452, 4.454)
Mechanical ventilation	2.464	0.312	0.000	11.75	(6.378, 21.649)
CRRT	0.911	0.268	0.001	2.487	(1.472, 4.202)
Department	0.064	0.08	0.430	1.066	(0.91, 1.248)
IL1	0.604	0.157	0.000	1.83	(1.345, 2.488)
IL2	0.406	0.1	0.000	1.5	(1.234, 1.824)
IL6	-0.119	0.1	0.231	0.887	(0.73, 1.079)
IL8	0.018	0.095	0.848	1.018	(0.846, 1.226)
IL10	-0.06	0.11	0.584	0.942	(0.76, 1.168)
TNF- α	0.077	0.114	0.502	1.08	(0.863, 1.351)
Procalcitonin	0.097	0.081	0.231	1.102	(0.940, 1.292)
Multivariate analysis					
Length of SICU stay	-1.046	0.199	0.000	0.351	(0.238, 0.519)
SICU readmission	0.963	0.258	0.000	2.62	(1.579, 4.347)
Mechanical ventilation	2.413	0.279	0.000	11.163	(6.461, 19.290)
CRRT	0.888	0.243	0.000	2.43	(1.508, 3.916)
IL1	0.618	0.127	0.000	1.855	(1.446, 2.38)
IL2	0.412	0.077	0.000	1.51	(1.299, 1.754)
SICU surgical intensive care unit, TNF- α tumor necrosis factor- α , IL interleukin, CRRT continuous renal replacement therapy					

Cytokine levels were increased in SICU readmission patients Of the 5,257 patients, 196 patients were readmitted to the SICU, giving a rate of 3.7%. In the readmitted group, the length of SICU stay and length of mechanical ventilation were much longer than those in the other group; the rates of mechanical ventilation, CRRT, tracheotomy and emergency surgery were much higher in patients who were readmitted

than those in patients who were not readmitted. According to the department, the highest readmission rate occurred in the general surgery department (5.0%).

To determine whether cytokine levels were associated with the SICU readmission rate, we assessed the difference between the two groups. The readmission group patients had increased levels of IL-1 β , IL-2, IL-6, IL-8, IL-10, TNF- α and procalcitonin (Table 4). Univariate and multivariate analyses showed that mechanical ventilation and the level of IL-2 could significantly influence SICU readmission, but no correlation was noted between IL-1 β , IL-6, IL-8, IL-10, TNF- α and procalcitonin levels and SICU readmission in the patients (Table 5).

Table 4
Cytokine levels in patients with or without SICU readmission (n = 5,257)

Variables	SICU readmission (n = 5,257)		z/χ ²	P value
	Yes (n = 196)	No (n = 5,061)		
Age (years)	65.4 ± 16.8	62.2 ± 16.3	-1.698	0.089
Sex, No. (%)			0.366	0.545
Male	121 (3.9%)	3015 (96.1%)		
Female	75 (3.5%)	2046 (96.5%)		
Length of SICU stay (h)	111.4 ± 142.6	62.7 ± 115.3	-6.999	0.000
Length of SICU stay			52.437	0.000
> 7 days	37 (10.9%)	301 (89.1%)		
≤ 7 days	159 (3.2%)	4,760 (96.8%)		
Length of mechanical ventilation (h)	363.1 ± 509.4	124.2 ± 712.2	-9.013	0.000
Mechanical ventilation			154.379	0.000
Yes	118 (9.6%)	1,110 (90.4%)		
No	78 (1.9%)	3,951 (98.1%)		
Tracheotomy				
Yes	45 (17.9%)	207 (82.1%)	147.202	0.000
No	151 (3.0%)	4,854 (97.0%)		
Length of CRRT	120.3 ± 84.7	68.3 ± 91.4	-3.854	0.000
CRRT			43.814	0.000
Yes	23 (13.0%)	154 (87.0%)		
No	173 (3.4%)	4,907 (96.6%)		
Emergency surgery				
Yes	86 (5.7%)	1,433 (94.3%)	21.965	0.000
No	110 (3.0%)	3,613 (97.0%)		
Not known	0 (0%)	15 (100%)		
Department			9.365	0.025
SICU surgical intensive care unit, TNF-α tumor necrosis factor-alpha, IL interleukin, CRRT continuous renal replacement therapy				

Variables	SICU readmission (n = 5,257)		z/χ ²	P value
	Yes (n = 196)	No (n = 5,061)		
General surgery	62 (5.0%)	1,166 (95.0%)		
Thoracic surgery	38 (3.0%)	1,235 (97.0%)		
Neurosurgery	31 (3.9%)	767 (96.1%)		
Endovascular surgery	20 (3.6%)	538 (96.4%)		
Orthopedics	11 (2.6%)	406 (97.4%)		
Urologic surgery	10 (3.2%)	307 (96.8%)		
Others	24 (3.6%)	642 (96.4%)		
IL-1β (pg/ml)			-3.775	0.000
Normal (≤ 5)	176 (3.5%)	4,878 (96.5%)		
5 ~ 10	12 (8.7%)	126 (91.3%)		
≥ 10	8 (12.3%)	57 (87.7%)		
IL-2 (U/ml)			-7.427	0.000
Normal (223–710)	76 (2.3%)	3,236 (97.7%)		
710-1,000	47 (5.2%)	860 (94.8%)		
1,000–2,000	48 (6.2%)	727 (93.8%)		
2,000–3,000	10 (6.0%)	156 (94.0%)		
≥ 3,000	15 (15.5%)	82 (84.5%)		
IL-6 (pg/ml)			-5.592	0.000
Normal (< 3.4)	10 (2.6%)	380 (97.4%)		
3.4–50	78 (2.9%)	2,724 (97.1%)		
50–100	30 (3.8%)	761 (96.2%)		
100–200	29 (4.8%)	571 (95.2%)		
≥ 200	49 (7.3%)	625 (92.7%)		
IL-8 (pg/ml)			-3.261	0.001
Normal (< 62)	148 (3.3%)	4,317 (96.7%)		

SICU surgical intensive care unit, TNF-α tumor necrosis factor-alpha, IL interleukin, CRRT continuous renal replacement therapy

Variables	SICU readmission (n = 5,257)		z/χ2	P value
	Yes (n = 196)	No (n = 5,061)		
62–100	22 (6.9%)	295 (93.1%)		
100–150	8 (4.7%)	164 (95.3%)		
150–200	5 (5.2%)	92 (94.8%)		
≥ 200	13 (6.3%)	193 (93.7%)		
IL-10 (pg/ml)			-4.357	0.000
Normal (< 9.1)	125 (3.1%)	3,948 (96.9%)		
9.1–20	41 (5.9%)	659 (94.1%)		
20–50	15 (5.1%)	282 (94.9%)		
50–100	6 (6.8%)	82 (93.2%)		
≥ 100	9 (9.1%)	90 (90.9%)		
TNF-α (pg/ml)			-4.474	0.000
Normal (< 8.1)	64 (2.5%)	2,487 (97.5%)		
8.1–15	58 (3.8%)	1,481 (96.2%)		
15–30	39 (5.6%)	657 (94.4%)		
30–50	19 (7.1%)	248 (92.9%)		
≥ 50	16 (7.8%)	188 (92.2%)		
Procalcitonin (ng/ml)			-5.911	0.000
Normal (< 0.5)	102 (2.6%)	3,766 (97.4%)		
0.5-2	38 (5.1%)	712 (94.9%)		
2–5	27 (8.8%)	281 (91.2%)		
5–10	15 (10.2%)	132 (89.8%)		
≥ 10	14 (7.6%)	170 (92.4%)		
SICU surgical intensive care unit, TNF-a tumor necrosis factor-alpha, IL interleukin, CRRT continuous renal replacement therapy				

Table 5
Analysis of cytokine levels in relation to SICU readmission of patients

Variables	β	SE	P value	OR	95% CI
Univariate analysis					
Sex	-0.065	0.178	0.717	0.937	(0.661, 1.329)
Length of SICU stay	-0.356	0.235	0.130	0.7	(0.442, 1.111)
Mechanical ventilation	1.315	0.2	0.000	3.724	(2.518, 5.508)
CRRT	0.385	0.306	0.208	1.47	(0.807, 2.678)
Department	0.068	0.069	0.328	1.07	(0.934, 1.226)
IL1	0.28	0.177	0.113	1.324	(0.936, 1.871)
IL2	0.249	0.095	0.009	1.283	(1.065, 1.545)
IL6	0.159	0.082	0.052	1.172	(0.999, 1.376)
IL8	-0.101	0.102	0.320	0.904	(0.740, 1.103)
IL10	-0.17	0.112	0.128	0.844	(0.677, 1.05)
TNF- α	-0.057	0.107	0.596	0.945	(0.766, 1.166)
Procalcitonin	0.018	0.084	0.835	1.018	(0.863, 1.200)
Multivariate analysis					
Mechanical ventilation	1.366	0.166	0.000	1.29	(1.134, 1.467)
IL2	0.254	0.066	0.000	3.921	(2.829, 5.434)
SICU surgical intensive care unit, TNF-a tumor necrosis factor-alpha, IL interleukin, CRRT continuous renal replacement therapy					

Correlation between cytokine levels in patients with SICU readmission and outcomes Among the 196 patients with SICU readmission, the cytokine levels of 187 patients readmission were tested and collected. Overall, 161 patients survived, and 26 patients died; the mortality rate was 13.9%, which was much higher than that seen with the first SICU admission (3.0%).

For the third SICU admission, 10 patients (5.3%, 10/187) were admitted, of which 8 patients were female, accounting for 80.0%. Seven patients survived, and 3 patients died, with a mortality rate of 30.0% (3/7), which was much higher than that of the first and second SICU admissions.

To determine the outcomes and risk factors, we assessed the difference between survivors and nonsurvivors. Nonsurvivors had increased levels of IL-2 and procalcitonin compared with survivors, but no correlation was noted between IL-1 β , IL-6, IL-8, IL-10 and TNF-a levels and outcomes in the patients.

Differences between the two groups were noted in the variables of age, length of SICU stay, mechanical ventilation, CRRT and department (Table 6).

Table 6
Outcomes and risk factors for patients readmitted to the SICU

Variable	Outcomes (n = 187)		t/z/χ ²	P value
	Nonsurvivors (n = 26)	Survivors (n = 161)		
Age	73.9 ± 15.8	63.9 ± 16.8	2.817	0.005
Sex			0.091	0.763
Male	16 (13.3%)	104 (86.7%)		
Female	10 (14.9%)	57 (85.1%)		
Length of SICU stay			4.586	0.032
> 7 days	9 (25.0%)	27 (75.0%)		
≤ 7days	17 (11.3%)	134 (88.7%)		
Admitted to SICU for the third time			0.86	0.354
Yes	2 (25.0%)	6 (75.0%)		
No	24 (13.4%)	155 (86.6%)		
Mechanical ventilation			7.986	0.005
Yes	22 (19.8%)	89 (80.2%)		
No	4 (5.3%)	72 (94.7%)		
CRRT			6.685	0.010
Yes	7 (31.8%)	15 (68.2%)		
No	19 (11.5%)	146 (88.5%)		
Department			11.380	0.007
General surgery	13 (22.0%)	46 (78.0%)		
Neurosurgery	5 (13.9%)	31 (86.1%)		
Endovascular surgery	4 (28.6%)	10 (71.4%)		
Others	4 (5.1%)	74 (94.9%)		
IL-1β (pg/ml)			-0.806	0.421
Normal (≤ 5)	25 (14.7%)	145 (85.3%)		

SICU surgical intensive care unit, TNF-α tumor necrosis factor-alpha, IL interleukin, CRRT continuous renal replacement therapy

Variable	Outcomes (n = 187)		t/z/χ ²	P value
	Nonsurvivors (n = 26)	Survivors (n = 161)		
5–10	0 (0%)	9 (100%)		
≥ 10	1 (12.5%)	7 (87.5%)		
IL-2 (U/ml)				
Normal (223–710)	5 (5.8%)	81 (94.2%)	-3.478	0.001
710–1,000	3 (9.4%)	29 (90.6%)		
1,000–2,000	11 (23.4%)	36 (76.6%)		
2,000–3,000	3 (30.0%)	7 (70.0%)		
≥ 3,000	4 (33.3%)	8 (66.7%)		
IL-6 (pg/ml)			-1.602	0.109
Normal (< 3.4)	0 (0%)	9 (100%)		
3.4–50	8 (10.7%)	67 (89.3%)		
50–100	5 (17.9%)	23 (82.1%)		
100–200	4 (13.8%)	25 (86.2%)		
≥ 200	9 (19.6%)	37 (80.4%)		
IL-8 (pg/ml)			-1	0.317
Normal (< 62)	18 (12.7%)	124 (87.3%)		
62–100	4 (19.0%)	17 (81.0%)		
100–150	1 (12.5%)	7 (87.5%)		
150–200	0 (0%)	4 (100%)		
≥ 200	3 (25.0%)	9 (75.0%)		
IL-10 (pg/ml)			-1.109	0.268
Normal (< 9.1)	16 (13.2%)	105 (86.8%)		
9.1–20	2 (5.1%)	37 (94.9%)		
20–50	3 (21.4%)	11 (78.6%)		

SICU surgical intensive care unit, TNF-α tumor necrosis factor-alpha, IL interleukin, CRRT continuous renal replacement therapy

Variable	Outcomes (n = 187)		t/z/χ2	P value
	Nonsurvivors (n = 26)	Survivors (n = 161)		
50–100	2 (50.0%)	2 (50.0%)		
≥ 100	3 (33.3%)	6 (66.7%)		
TNF-α (pg/ml)			-1.273	0.203
Normal (< 8.1)	5 (7.0%)	66 (93.0%)		
8.1–15	11 (19.0%)	47 (81.0%)		
15–30	5 (13.9%)	31 (86.1%)		
30–50	3 (20.0%)	12 (80.0%)		
≥ 50	1 (16.7%)	5 (83.3%)		
Procalcitonin (ng/ml)			-2.031	0.042
Normal (< 0.5)	10 (8.7%)	105 (91.3%)		
0.5-2	5 (14.3%)	30 (85.7%)		
2–5	4 (23.5%)	13 (76.5%)		
5–10	1 (20.0%)	4 (80.0%)		
≥ 10	3 (25.0%)	9 (75.0%)		
SICU surgical intensive care unit, TNF-a tumor necrosis factor-alpha, IL interleukin, CRRT continuous renal replacement therapy				

The prognostic significance of IL-1β, IL-2, IL-6, IL-8, IL-10, TNF-α and procalcitonin Overall 158 (3.0%) of 5,257 patients died, and 5,099 (97.0%) remained alive. The overall survival for patients with higher levels of IL-1β, IL-2, IL-6, IL-8, IL-10, TNF-α and procalcitonin was significantly lower than that for patients with normal levels (Fig. 1) (Table 7).

Table 7
Survival time of the patients

Cytokines		Survival time (95% CI) (days)
IL-1 β (pg/ml)		
	Normal (≤ 5)	57 (40.004, 73.996)
	5 ~ 10	68 (39.625, 68.017)
	≥ 10	28 (13.122, 28.360)
IL-2 (U/ml)		
	Normal (223–710)	77 (56.907, 97.093)
	710-1,000	41 (16.838, 65.162)
	1,000–2,000	51 (36.087, 65.913)
	2,000–3,000	63 (14.28, 111.72)
	$\geq 3,000$	14 (2.452, 25.548)
IL-6 (pg/ml)		
	Normal (< 3.4)	16 (15.26,18.651)
	3.4–50	77 (43.82,110.18)
	50–100	37 (15.72,58.28)
	100–200	28 (15.495,40.505)
	≥ 200	58 (33.834,82.166)
IL-8 (pg/ml)		
	Normal (< 62)	57 (29.215, 84.785)
	62–100	41 (9.561, 72.439)
	100–150	58 (5.168, 110.832)
	150–200	19 (15.876, 22.702)
	≥ 200	78 (55.499, 100.945)
IL-10 (pg/ml)		
	Normal (< 9.1)	51 (30.82, 71.18)
	9.1–20	47 (36.221, 142.982)
	20–50	63 (28.065, 97.935)
TNF-a tumor necrosis factor-alpha, IL interleukin		

Cytokines	Survival time (95% CI) (days)
50–100	35 (1.411, 68.589)
≥ 100	26 (8.111, 43.889)
TNF-α (pg/ml)	
Normal (< 8.1)	77 (51.041, 102.959)
8.1–15	45 (12.678, 77.322)
15–30	47 (17.999, 76.001)
30–50	63 (26.616, 99.384)
≥ 50	58 (32.077, 58.024)
Procalcitonin (ng/ml)	
Normal (< 0.5)	66 (29.409, 102.591)
0.5-2	58 (23.514, 92.486)
2–5	25 (5.611, 55.102)
5–10	51 (27.84, 74.16)
≥ 10	37 (2.289, 71.711)
TNF-a tumor necrosis factor-alpha, IL interleukin	

Discussion

Despite advances in supportive therapy and many clinical trials, among critically ill patients, adverse outcomes (sepsis, septic shock, organ dysfunction/failure, and mortality) remain high[11, 12]. Consequently, there is an urgent demand for better identification of variables for high-risk patients. At present, the determination of ICU patient risk mainly relies on clinical judgment and severity scores (such as APACHE scores), which incorporate patients' previous health statuses, along with clinical and laboratory variables, which track the function of multiple organ systems[13–16]. In recent decades, our knowledge of the biochemical processes underlying critical illness has considerably improved. We realized that cytokines perform important roles in host defense and maintenance of tissue homeostasis; however, abnormal or excessive production of cytokines disrupts these functions, resulting in inflammation and tissue injury[17], and there is strong evidence that cytokines work as important mediators of inflammatory and immunologic diseases and that elevated cytokine levels can contribute to organ dysfunction[18–20]. Evidence suggests that cytokines, including IL-8, TNF-a, and IL-10, strongly predict clinical outcome alone or in combination with other variables or widely accepted severity scores[21, 22].

Our study focused on critically ill patients after surgery, who received almost all possible surgeries in the SICU. For the first SICU admission, the mortality rate of the entire group was 3.0% (158/5257), and the readmission rate was 3.7% (196/5,257). In agreement with other findings, we found higher levels of IL-1 β , IL-2, IL-6, IL-8, IL-10, TNF- α and procalcitonin in nonsurvivors than in survivors[17, 21]. Univariate and multivariate analyses showed that the influence of IL-1 β (OR = 1.855, P = 0.000) and IL-2 (OR = 1.51, P = 0.000) on survival was significant. We also showed that cytokine levels correlated positively with the SICU readmission rate. Although the univariate and multivariate analyses only showed that the levels of IL-2 (OR = 3.921, P = 0.000) could significantly influence the readmission rate, the SICU readmission rate was increased in patients with high levels of IL-1 β , IL-2, IL-6, IL-8, IL-10, TNF- α and procalcitonin compared with that in patients with normal levels. Our study revealed that in the entire population of critically ill patients after surgery, cytokines represent independent outcome predictors; in addition, IL-1 β and IL-2 can determine mortality, and IL-2 can also influence the readmission rate.

Similar results were noted at SICU readmission. In total, 187 patients were included, including 161 survivors and 26 nonsurvivors, with a mortality rate of 13.9% (26/187), which was much higher than that for the first SICU admission (3.0%). We still noted increased IL-2 levels in nonsurvivors ($z=-3.478$, $p = 0.001$). As a key cytokine involved in the immune response, IL-2 regulation can promote the differentiation of T cells and enhance the killing effect[3]. In a previous report, IL-2 levels were evaluated in the oral fluids of patients with hepatitis C or B and HIV[23]. Therefore, we can assume that IL-2 has a distinctive value for determining the state of local immunity in individuals, especially in critically ill patients. This has led to the development of novel therapeutic strategies using regulatory cytokines or cytokine-targeted biologics for the treatment of various diseases. According to some reports, the administration of low-dose IL-2 has resulted in promising results in treating autoimmune conditions such as chronic refractory graft-versus-host disease (GVHD), hepatitis C virus-induced vasculitis, and type 1 diabetes [24–26]. Some clinical trials have suggested that low-dose IL-2 might be effective in the treatment of systemic lupus erythematosus[27, 28].

We also analyzed patients who were admitted to the SICU for a third time. In total, 10 patients were included, including 2 males and 8 females and 3 nonsurvivors and 7 survivors, with a mortality of 30.0% (3/10). We also noted increased IL-2 levels in nonsurvivors. As previously mentioned, we were able to demonstrate that older age, longer SICU stay, emergency surgery, high rate of mechanical ventilation and CRRT were associated with mortality and SICU readmission. One hypothesis is that these factors, including cytokine levels, correlate positively with the severity of critical illness and organ dysfunction. Regrettably, we omitted the data of the APACHE II score and could not analyze its association with outcomes. However, some studies have demonstrated that in nonseptic patients, cytokines represent independent outcome predictors along with disease severity scores, including APACHE II scores[4, 29]. However, other reports show contrasting results: cytokine levels cannot predict patient outcomes in nonseptic SICU patients[30, 31]. Differences in patient condition (especially at diagnosis), the cytokine assays used and the data analysis methods used may explain the disparate results.

Limitations

Potential limitations of this work include two points. First, we detected cytokines only on admission to the SICU. Sequential assessments of changes in cytokine levels may provide stronger evidence for the associations of the variables and outcomes. Second, we omitted the APACHE II score data, so the association between it, cytokine level and severity of disease could not be analyzed. Future studies should be undertaken to look at the association in critically ill patients after surgery.

Conclusion

In summary, the mortality rate increased with increasing number of admissions to the SICU (3.0%<13.9%<30.0%). In critically ill patients after surgery, cytokine levels, including IL-1 β , IL-2, IL-6, IL-8, IL-10, TNF- α and procalcitonin levels, on admission to the SICU can predict outcome. Importantly, IL-2 seems to be the sole variable determining the outcome. Further studies are needed to explore the combined effect of cytokines and the sequential changes in cytokine levels in critically ill surgical patients.

Abbreviations

MOF

multiple organ failure; TNF- α :tumor necrosis factor-alpha; IL:interleukin; SICU:surgical intensive care unit; SIRS:systemic inflammatory response syndrome; CRRT:continuous renal replacement therapy; APACHE II:acute physiology and chronic health evaluation; HIV:human immunodeficiency virus; GVHD:graft-versus-host disease; IQRs:interquartile ranges; SDs:standard deviations; OR:odds ratio; CI:confidence intervals.

Declarations

Acknowledgements

We would like to thank AJE (<https://secure.aje.com/>) for English language editing.

Authors' contribution:

Wenyan Pan and Yuxia Zhang conceived of this study. Yamin Yan collected the information, performed this study and drafted the article. Xiaorong Wang and Yan Hu participated in training the information collector and collecting the data. Zhenghong Yu and Yingjia Tang participated in check the quality of the collected data. Jingjing Li and Jinghua Mei participated in collecting and checking the patients' data. All authors have read and approved this article.

Funding

This work was supported by Youth Program of Zhongshan Hospital, Fudan University (no. 2019ZSQN01), Fuxing Nursing Program of Fudan University (no. FNF201945) and Program of Fudan University "Double First-Class Discipline Construction"(no. 2018-40-22)".

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to ownership by the Department of SICU, Zhongshan Hospital, Fudan University, Shanghai, China, but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The procedure mentioned in this study was in accordance with the standards of the Ethics Committee on Human Experimentation of Zhongshan Hospital, Fudan University(No. B2019-009). Informed consent from individual patients was waived because all data were anonymized for research purposes.

Consent for publication

Not applicable.

Competing interests

All the authors declare that they have no competing interests.

References

1. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. *JAMA*. 2001;286:1754–8.
2. Oberholzer A, Oberholzer C, Moldawer LL. Cytokine signaling–regulation of the immune response in normal and critically ill states. *Crit Care Med*. 2000;28:N3–12.
3. Huang C, Zhou L, Chang X, Pang X, Zhang H, Zhang S. B7-H3, B7-H4, Foxp3 and IL-2 expression in cervical cancer: Associations with patient outcome and clinical significance. *Oncol Rep*. 2016;35:2183–90.
4. Dimopoulou I, Orfanos S, Kotanidou A, Livaditi O, Giamarellos-Bourboulis E, Athanasiou C, Korovesi I, Sotiropoulou C, Kopterides P, Ilias I, et al. Plasma pro- and anti-inflammatory cytokine levels and outcome prediction in unselected critically ill patients. *Cytokine*. 2008;41:263–7.
5. Netea MG, van der Meer JW, van Deuren M, Kullberg BJ. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? *Trends Immunol*. 2003;24:254–8.

6. Shimazui T, Matsumura Y, Nakada TA, Oda S. Serum levels of interleukin-6 may predict organ dysfunction earlier than SOFA score. *Acute Med Surg.* 2017;4:255–61.
7. Quispe EA, Li XM, Yi H. Comparison and relationship of thyroid hormones, IL-6, IL-10 and albumin as mortality predictors in case-mix critically ill patients. *Cytokine.* 2016;81:94–100.
8. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. *J Infect Dis.* 2000;181:176–80.
9. Sarbinowski R, Arvidsson S, Tylman M, Oresland T, Bengtsson A. Plasma concentration of procalcitonin and systemic inflammatory response syndrome after colorectal surgery. *Acta Anaesthesiol Scand.* 2005;49:191–6.
10. Dimopoulou I, Armaganidis A, Douka E, Mavrou I, Augustatou C, Kopterides P, Lyberopoulos P, Tzanela M, Orfanos SE, Pelekanou E, et al. Tumour necrosis factor-alpha (TNFalpha) and interleukin-10 are crucial mediators in post-operative systemic inflammatory response and determine the occurrence of complications after major abdominal surgery. *Cytokine.* 2007;37:55–61.
11. Resche-Rigon M, Azoulay E, Chevret S. Evaluating mortality in intensive care units: contribution of competing risks analyses. *Crit Care.* 2006;10:R5.
12. Fatani SH, Al-Amodi AAAL, Kamel HS, Al-Khatieb HF, Bader K. H: Assessment of tumor necrosis factor alpha polymorphism TNF-alpha-238 (rs 361525) as a risk factor for development of acute kidney injury in critically ill patients. *Mol Biol Rep.* 2018;45:839–47.
13. Akavipat P, Thinkhamrop J, Thinkhamrop B, Sriraj W. Acute Physiology and Chronic Health Evaluation (Apache) II Score - the Clinical Predictor in Neurosurgical Intensive Care Unit. *Acta Clin Croat.* 2019;58:50–6.
14. Yalcin M, Godekmerdan E, Tayfur K, Yazman S, Urkmez M, Ata Y. The APACHE II Score as a Predictor of Mortality After Open Heart Surgery. *Turk J Anaesthesiol Reanim.* 2019;47:41–7.
15. Basile-Filho A, Lago AF, Meneguetti MG, Nicolini EA, Rodrigues LAB, Nunes RS, Auxiliadora-Martins M, Ferez MA. The use of APACHE II, SOFA, SAPS 3, C-reactive protein/albumin ratio, and lactate to predict mortality of surgical critically ill patients: A retrospective cohort study. *Med (Baltim).* 2019;98:e16204.
16. Korkmaz Toker M, Gulleroglu A, Karabay AG, Bicer IG, Demiraran Y. SAPS III or APACHE IV: Which score to choose for acute trauma patients in intensive care unit? *Ulus Travma Acil Cerrahi Derg.* 2019;25:247–52.
17. Jordan SC, Choi J, Kim I, Wu G, Toyoda M, Shin B, Vo A. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade. *Transplantation.* 2017;101:32–44.
18. Pinargote-Celorio H, Miralles G, Cano M, Caparros E, Portilla J, Gonzalez-Alcaide G, Ramos Rincon JM. Cytokine levels predict 30-day mortality in octogenarians and nonagenarians with community-acquired pneumonia: a retrospective observational study. *Eur J Clin Microbiol Infect Dis.* 2020;39:299–307.

19. Landegger LD, Vasilijic S, Fujita T, Soares VY, Seist R, Xu L, Stankovic KM. Cytokine Levels in Inner Ear Fluid of Young and Aged Mice as Molecular Biomarkers of Noise-Induced Hearing Loss. *Front Neurol*. 2019;10:977.
20. Hardy-Werbin M, Rocha P, Arpi O, Taus A, Nonell L, Duran X, Villanueva X, Joseph-Pietras D, Nolan L, Danson S, et al. Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. *Oncoimmunology*. 2019;8:e1593810.
21. Heper Y, Akalin EH, Mistik R, Akgoz S, Tore O, Goral G, Oral B, Budak F, Helvaci S. Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock. *Eur J Clin Microbiol Infect Dis*. 2006;25:481–91.
22. Livaditi O, Kotanidou A, Psarra A, Dimopoulou I, Sotiropoulou C, Augustatou K, Papasteriades C, Armaganidis A, Roussos C, Orfanos SE, Douzinas EE. Neutrophil CD64 expression and serum IL-8: sensitive early markers of severity and outcome in sepsis. *Cytokine*. 2006;36:283–90.
23. Azatyan V, Yessayan L, Shmavonyan M, Melik-Andreasyan G, Perikhanyan A, Porkshenyan K. Evaluation of IL-2, IL-10, IL-4 and -interferon levels in the oral fluids of patients with hepatitis C, B and HIV. *J Infect Dev Ctries*. 2019;13:69S–74S.
24. Tomova R, Antonov K, Ivanova A, Jacobs JJ, Koten JW, Den Otter W, Krastev Z. Low-dose IL-2 therapy reduces HCV RNA and HBV DNA: case report. *Anticancer Res*. 2009;29:5241–4.
25. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Treister NS, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. *N Engl J Med*. 2011;365:2055–66.
26. Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwaig M, Bernard C, Klatzmann D. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol*. 2013;1:295–305.
27. He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, Liu J, Zhang X, Jin Y, Wang Y, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. *Ann Rheum Dis*. 2020;79:141–9.
28. Ballesteros-Tato A, Papillion A. Mechanisms of action of low-dose IL-2 restoration therapies in SLE. *Curr Opin Immunol*. 2019;61:39–45.
29. Rodriguez-Gaspar M, Santolaria F, Jarque-Lopez A, Gonzalez-Reimers E, Milena A, de la Vega MJ, Rodriguez-Rodriguez E, Gomez-Sirvent JL. Prognostic value of cytokines in SIRS general medical patients. *Cytokine*. 2001;15:232–6.
30. Friedland JS, Porter JC, Daryanani S, Bland JM, Screatton NJ, Vesely MJ, Griffin GE, Bennett ED, Remick DG. Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit. *Crit Care Med*. 1996;24:1775–81.
31. Bonville DA, Parker TS, Levine DM, Gordon BR, Hydo LJ, Eachempati SR, Barie PS. The relationships of hypocholesterolemia to cytokine concentrations and mortality in critically ill patients with

Figures

Figure 1

Association between overall survival and IL-1 β , IL-2, IL-6, IL-8, IL-10, TNF-a and procalcitonin levels in 5,257 patients. (A-G) Patients with higher levels of IL-1 β , IL-2, IL-6, IL-8, IL-10, TNF-a and procalcitonin showed longer survival times than those with normal levels.